secwatch / observer
8-K filed May 14, 2024, 7:59 PM ET ticker NSPR CIK 0001433607
earnings confidence high sentiment neutral materiality 0.65

InspireMD Q1 revenue up 22% to $1.51M; net loss widens to $7.0M ($0.21/sh)

InspireMD, Inc.

2024-Q1 EPS reported -$0.21 revenue$1,511,000

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

InspireMD, Inc. reported first quarter ended March 31, 2024 results: revenue $1,511,000, net income $7,032,000, EPS $0.21 per basic and diluted share.

Period
first quarter ended March 31, 2024
Revenue
$1,511,000
Net income
$7,032,000
EPS
$0.21 per basic and diluted share
Result
reported results
Exact text from the filing
For the first quarter of 2024, total revenue increased 22.0%, to $1,511,000, from $1,239,000 during the first quarter of 2023. This increase was predominantly driven by growth in existing markets . Gross profit for the first quarter of 2024 decreased by $81,000, or 21.6%, to $292,000, compared to a gross profit of $373,000 for the first quarter of 2023. This decrease resulted primarily from higher training costs of new hires to build capacity for anticipated increased volume requirements . Gross margin (gross profit as a percentage of revenue) decreased to 19.4% during the three months ended March 31, 2024, from 30.1% during the three months ended March 31, 2023. Total operating expenses for the first quarter of 2024 were $7,706,000, an increase of $2,952,000, or 62.1% compared to $4,754,000 for the first quarter of 2023. This increase was primarily due to higher share-based compensation resulting from the recognition of grants made during the second quarter of 2023 and the first quart
View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

InspireMD, Inc. filing history →

Source: SEC EDGAR
accession 0001493152-24-019080
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.